# The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

Study · id `cardio:ct-nct05532800` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05532800](<https://clinicaltrials.gov/study/NCT05532800>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05532800

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 255 participants.

## Technical summary

Registry record NCT05532800. Randomized; quadruple masking; primary purpose treatment. Start 2022-02-28 (actual); primary completion 2023-02-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 255 participants (enrolled count; ClinicalTrials.gov record NCT05532800, source copy `cardio:ctgov-nct05532800-2023-03-15`, retrieved 2026-10-31)
- Started: 2022-02-28 (actual) (ClinicalTrials.gov record NCT05532800, source copy `cardio:ctgov-nct05532800-2023-03-15`, retrieved 2026-10-31)
- Primary completion: 2023-02-09 (actual) (ClinicalTrials.gov record NCT05532800, source copy `cardio:ctgov-nct05532800-2023-03-15`, retrieved 2026-10-31)
- Completion: 2023-02-09 (actual) (ClinicalTrials.gov record NCT05532800, source copy `cardio:ctgov-nct05532800-2023-03-15`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT05532800, source copy `cardio:ctgov-nct05532800-2023-03-15`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05532800-2023-03-15`, retrieved 2026-10-31)

## The registry's words

- Brief title: The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia
- Condition: Hyperlipemia
- Intervention (Drug): JS002
- Intervention (Drug): Placebo
- Lead sponsor: Shanghai Junshi Bioscience Co., Ltd.
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

## Provenance

Content hash: 4f208eb5029ac36c7de054a4a2c9acfbe33e77b7a6882d1e72d557b4cdf9103a
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
